Comparative Stroke, Bleeding, and Mortality

ARTICLE IN PRESS Supplementary Table 4 Demographic and Clinical Characteristics of Medicare Beneficiaries Initiating Warfarin, Dabigatran, Rivaroxaban, or Apixaban for Nonvalvular Atrial Fibrillation from 2010 to 2015, after Inverse Probability of Treatment Weighting Characteristic, % Warfarin (n = 183,003 ) * Dabigatran (n = 86,293 ) * Rivaroxaban (n = 106,369 ) * Apixaban (n = 72,921 ) * Maximum Pairwise SMD after Weighting Age, years (mean) 75.2 75.1 75.1 75.1 0.01 Age group, y 65-74 50.5 50.7 50.2 50.1 0.01 75-84 39.1 39.8 40.6 40.5 0.03 85+ 10.3 9.5 9.2 9.3 0.04 Female 47.2 46.9 47.1 47.2 0.01 Race/ethnicity White 92.0 92.1 92.0 92.0 0.00 Black 3.6 3.5 3.5 3.6 0.01 Other 4.4 4.4 4.5 4.4 0.00 Medical comorbidities Diabetes 33.4 33.0 33.1 33.0 0.01 Hypercholesterolemia 38.6 38.7 38.6 38.6 0.00 Hypertension 86.7 86.5 86.6 86.5 0.01 Kidney failure Acute 4.2 4.0 4.0 4.2 0.01 Chronic 10.5 10.1 10.2 10.4 0.01 Obesity 16.3 16.3 16.2 16.3 0.00 Peptic ulcer disease 0.4 0.4 0.4 0.4 0.00 Prior hospitalized bleeding 0.5 0.4 0.5 0.5 0.00 Smoking 21.6 21.5 21.5 21.7 0.00 Cardiovascular disease Acute myocardial infarction Past 1-30 days 1.3 1.3 1.3 1.3 0.01 Past 31-183 days 0.8 0.8 0.8 0.8 0.01 Coronary revascularization 15.4 15.0 15.1 15.2 0.01 Heart failure Hospitalized 3.3 3.1 3.1 3.2 0.01 Outpatient 11.8 11.6 11.8 11.7 0.01 Other ischemic heart disease 44.1 43.6 43.7 43.7 0.01 Stroke Past 1-30 days 2.0 1.9 2.0 2.0 0.00 Past 31-183 days 1.3 1.3 1.3 1.3 0.00 Other Transient ischemic attack 6.4 6.3 6.3 6.3 0.00 Cardioablation 2.2 2.2 2.2 2.2 0.00 Cardioversion 9.3 9.6 9.5 9.7 0.01 Other medical conditions Falls 4.7 4.6 4.6 4.6 0.01 Fractures 1.3 1.3 1.3 1.3 0.00 Syncope 9.1 8.9 9.0 9.0 0.01 Walker use 2.4 2.3 2.3 2.3 0.01 CHA 2 DS 2 -VASc scor e y 0-1 3.1 3.2 3.1 3.1 0.01 2 16.1 16.6 16.4 16.3 0.01 3 28.9 29.2 29.1 29.0 0.01 ≥ 4 51.9 51.0 51.4 51.5 0.01 HAS-BLED score z 1 8.9 9.1 9.0 9.0 0.01 2 45.3 45.9 45.7 45.5 0.01 3 31.8 31.5 31.6 31.7 0.01 ≥ 4 13.9 13.5 13.7 13.8 0.01 Medication use General Estrogen replacement 2.1 2.1 2.1 2.1 0.00 9.e3 The American Journal of Medicine, Vol 000, No 000, && 2019